

COMUNICATO STAMPA

**Conclusione con successo dell'operazione di *accelerated book-building*
promossa dall'azionista BFF Luxembourg S.à r.l.**

Milano, 12 febbraio 2021.

Facendo seguito al comunicato diffuso in data 11 febbraio 2021, e su richiesta dell'azionista BFF Luxembourg S.à r.l. ("**BFF Lux**"), si riporta di seguito il testo del comunicato stampa relativo alla conclusione della procedura di *accelerated book-building* su azioni ordinarie di Banca Farmafactoring S.p.A. da parte di BFF Lux.

Il presente comunicato è disponibile on-line sul sito del Gruppo BFF www.bffgroup.com nella sezione *Investors > Comunicati Stampa*.

BFF Banking Group

BFF Banking Group è l'operatore leader specializzato nella gestione e nello smobilizzo pro soluto di crediti commerciali vantati nei confronti delle Pubbliche Amministrazioni in Europa. Il Gruppo opera in Italia, Croazia, Francia, Grecia, Polonia, Portogallo, Repubblica Ceca, Slovacchia e Spagna, oltre a Germania, Olanda e Irlanda dove è attivo attraverso depositi on-line, salendo così a un totale di 12 Paesi in Europa. BFF è quotato in Borsa Italiana. Nel 2020 ha registrato un Utile Netto Consolidato e Rettificato di € 97,6 milioni, con un coefficiente CET1 di Gruppo a fine dicembre 2020 pari a 15,5%. www.bffgroup.com

Contatti

Investor Relations

Caterina Della Mora, Claudia Zolin
investor.relations@bffgroup.com
+39 02 49905 631 | +39 02 49905 620
+39 335 1295008

Media Relations

Alessia Barrera, Gianluca Basciu
newsroom@bffgroup.com
+39 02 49905 616 | +39 02 49905 623
+39 340 3434065

IL PRESENTE COMUNICATO NON È DESTINATO, IN TUTTO O IN PARTE, ALLA PUBBLICAZIONE, DISTRIBUZIONE O CIRCOLAZIONE, DIRETTA O INDIRETTA, NEGLI O DAGLI STATI UNITI D'AMERICA, CANADA, AUSTRALIA, GIAPPONE, SUD AFRICA O IN QUALSIASI ALTRO PAESE IN CUI TALE PUBBLICAZIONE, DISTRIBUZIONE O CIRCOLAZIONE POSSA COSTITUIRE UNA VIOLAZIONE DELLE NORMATIVE IVI APPLICABILI

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION

COMUNICATO STAMPA

Conclusa con successo l'operazione di *accelerated bookbuilding* promossa da BFF Luxembourg S.à r.l. in Banca Farmafactoring S.p.A.
BFF Luxembourg S.à r.l. completa la sua uscita da Banca Farmafactoring S.p.A.

Il corrispettivo dell'operazione ammonta a Euro 66 milioni, risultanti dalla vendita di n. 11.806.970 azioni ordinarie di Banca Farmafactoring S.p.A. ad un prezzo di Euro 5,60 per azione.

Lussemburgo, 12 febbraio 2021. Facendo seguito al comunicato stampa pubblicato in data 11 febbraio 2021, BFF Luxembourg S.à r.l. ("**BFF Lux**") annuncia di aver completato con successo la procedura di *accelerated bookbuilding* (l'"**Offerta**") avente ad oggetto azioni ordinarie di Banca Farmafactoring S.p.A. ("**BFF**" o la "**Società**"). BFF Lux comunica di aver ceduto a investitori istituzionali n. 11.806.970 azioni ordinarie detenute in BFF, corrispondenti a circa il 6,92% del capitale sociale della Società alla data del presente comunicato, al prezzo di Euro 5,60 per azione.

Il corrispettivo complessivo è stato pari a Euro 66 milioni. Il regolamento dell'operazione è previsto in data 16 febbraio 2021.

Successivamente alla conclusione dell'Offerta e in seguito all'esercizio da parte dell'Amministratore delegato della Società della *call option* con consegna fisica prevista ai sensi del relativo "Lock up and Option Agreement", BFF Lux completerà la sua uscita da BFF.

Jefferies è stata incaricata da BFF Lux quale Sole Global Coordinator dell'Offerta (il "**Sole Global Coordinator**").

Rothschild & Co e Linklaters hanno agito, rispettivamente, in qualità di *financial advisor* e consulente legale di BFF Lux.

La Società non riceverà alcun provento dall'Offerta.

* * *

This announcement is not for publication, distribution or release, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Canada, South Africa, Australia or Japan or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States without registration thereunder or pursuant to an available exemption therefrom. Neither this document nor the information contained herein constitutes or forms part of an offer to sell, or the solicitation of an offer to buy, securities in the United States. There will be no public offer of any securities in the United States or in any other jurisdiction.

In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended from time to time (the "**Prospectus Regulation**") together with any delegated act and implementing measures. In the United Kingdom this announcement is directed exclusively at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "**Order**") or (ii) who fall within Article 49(2)(A) to (D) of the Order, and (iii) to whom it may otherwise lawfully be communicated; any other persons in the United Kingdom should not take any action on the basis of this announcement and should not act on or rely on it. This announcement is not an offer of securities or investments for sale nor a solicitation of an offer to buy securities or investments in any jurisdiction where such offer or solicitation would be unlawful. No action has been taken that would permit an offering of the securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

In connection with any offering of the shares of Banca Farmafactoring S.p.A. (the "**Shares**"), the Sole Global Coordinator and any of its affiliates acting as an investor for its own account may take up as a proprietary position any Shares and in that capacity, may retain, purchase or sell for their own account such Shares. In addition, the Sole Global Coordinator or its affiliates may enter into financing arrangements and swaps with investors in connection with which the Sole Global Coordinator (or its affiliates) may from time to time acquire, hold or dispose of Shares. The Sole Global Coordinator does not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligation to do so.

Any offer and sale of the Shares in Canada will be made on a private placement basis only and is exempt from the requirement that the Company prepares and files a prospectus under applicable Canadian securities laws. Any resale of the Shares into Canada must be made in accordance with applicable Canadian securities laws, which may vary depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus requirements or otherwise under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the Shares outside of Canada. There will be no public offering of the Shares in Canada. This Announcement does not contain all of the information that would normally appear in a prospectus under applicable Canadian securities laws. No securities commission or similar authority in Canada has reviewed or in any way passed upon this Announcement or the merits of the Shares. Any representation to the contrary is an offense. This Announcement is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the Shares in Canada.

No offer and sale of Shares is or will be made in Canada, except to persons who are: (a) a "accredited investor" within the meaning of Section 1.1 of National Instrument 45-106 – Prospectus Exemptions ("NI 45-106") of the Canadian Securities Administrators or subsection 73.3(1) of the Securities Act (Ontario) (the "OSA"), as applicable, and is either purchasing the Shares as principal for its own account, or is deemed to be purchasing the Shares as principal for its own account in accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (b) not created or used solely to purchase or hold the Shares as an accredited investor under NI 45-106; (c) a "permitted client" within the meaning of National Instrument 31-103 – Registration Requirements, Exemptions and Ongoing Registrant Obligations ("NI 31-103") of the Canadian Securities Administrators; and (d) entitled under applicable Canadian securities laws to purchase the Shares without the benefit of a prospectus under such securities laws.